相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
William J. Gradishar et al.
EUROPEAN JOURNAL OF CANCER (2013)
Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer
Teresa Cabezon et al.
MOLECULAR & CELLULAR PROTEOMICS (2013)
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
Stefan Glueck et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
Adam Brufsky et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
Emilia Montagna et al.
CLINICAL BREAST CANCER (2012)
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2012)
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Jonas Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
Christoph Thomssen et al.
ONCOLOGY (2012)
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
M. N. Fornier et al.
ANNALS OF ONCOLOGY (2011)
Src: a potential target for the treatment of triple-negative breast cancer
D. Tryfonopoulos et al.
ANNALS OF ONCOLOGY (2011)
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2011)
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO
Xavier Pivot et al.
EUROPEAN JOURNAL OF CANCER (2011)
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors
Lauren L. C. Marotta et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells
Tongrui Liu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Deconstructing the molecular portraits of breast cancer
Aleix Prat et al.
MOLECULAR ONCOLOGY (2011)
Reputation and Precedent in the Bevacizumab Decision
Daniel Carpenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Directed Therapy of Subtypes of Triple-Negative Breast Cancer
Lisa A. Carey
ONCOLOGIST (2011)
Triple-Negative Breast Cancer: An Unmet Medical Need
Clifford A. Hudis et al.
ONCOLOGIST (2011)
Molecular Stratification of Triple-Negative Breast Cancers
Charles M. Perou
ONCOLOGIST (2011)
Intratumoral Expression Level of Epidermal Growth Factor Receptor and Cytokeratin 5/6 Is Significantly Associated With Nodal and Distant Metastases in Patients With Basal-like Triple-Negative Breast Carcinoma
Lisa M. Sutton et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Christopher Lobo et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
H. Wildiers et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H. Barrios et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes
Alison Jones et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Triple-Negative Breast Cancer Role of Antiangiogenic Agents
Sally Greenberg et al.
CANCER JOURNAL (2010)
SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).
J. Baselga et al.
CANCER RESEARCH (2010)
A Phase 1b Study To Assess the Safety and Tolerability of the PARP Inhibitor Iniparib (BSI-201) in Combination with Irinotecan for the Treatment of Patients with Metastatic Breast Cancer (MBC)
S. Moulder et al.
CANCER RESEARCH (2010)
Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
Kedar Hastak et al.
CANCER RESEARCH (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy
Stacy Moulder et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
N. Turner et al.
ONCOGENE (2010)
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
B. Corkery et al.
ANNALS OF ONCOLOGY (2009)
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
Giulia Bianchi et al.
ANTI-CANCER DRUGS (2009)
Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells
Masayoshi Kobune et al.
CANCER SCIENCE (2009)
Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
Farrah Kassam et al.
CLINICAL BREAST CANCER (2009)
Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2009)
The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review
Jacek Jassem et al.
EUROPEAN JOURNAL OF CANCER (2009)
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan L. Ellard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
Eloisi Caldas-Lopes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
Marisa G. Ponzo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2008)
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Bryan P. Schneider et al.
CLINICAL CANCER RESEARCH (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
DNA repair pathways as targets for cancer therapy
Thomas Helleday et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
BRCA1 dysfunction in sporadic basal-like breast cancer
N. C. Turner et al.
ONCOGENE (2007)
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
Jason I. Herschkowitz et al.
GENOME BIOLOGY (2007)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
Biomarkers and multiple drug resistance in breast cancer
L. O'Driscoll et al.
CURRENT CANCER DRUG TARGETS (2006)
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
A. S. Doane et al.
ONCOGENE (2006)
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
RK Jain et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype
SR Lakhani et al.
CLINICAL CANCER RESEARCH (2005)
Molecular mechanisms of drug resistance
DB Longley et al.
JOURNAL OF PATHOLOGY (2005)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
WD Foulkes et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
分享论文
